EDITORIAL |
Tirat Carmel Mental Health Center, POB 9, Tirat Carmel 30200, Israel. Email: poyurovs{at}tx.technion.ac.il
M.P. is a member of the advisory board of Schering Plough, and served as a consultant for akathisia studies for Acadia Pharmaceuticals.
Akathisia remains one of the most prevalent and distressful antipsychotic-induced adverse events. Effective and well-tolerated treatment is a major unmet need in akathisia that merits a search for new remedies. Accumulating evidence indicates that agents with marked serotonin-2A receptor antagonism may represent a new class of potential anti-akathisia treatment.
Related articles in BJP:
Read all eLetters